J&J’s Sirturo Wins U.S. Approval to Treat Drug-Resistant TB

J&J’s Sirturo Wins U.S. Approval to Treat Drug-Resistant TB

Brent Lewin/Bloomberg

Johnson &Johnson sought approval for the drug, known chemically as bedaquiline, based on the second phase of clinical trials. The company plans to start a final-phase trial in the first quarter of 2013 to study bedaquiline use for nine months compared with a placebo.